A study of biomarker predicting the effect of Nivolumab for unresectable advanced or recurrent gastric cancer.
Phase of Trial: Phase IV
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Biomarker; Therapeutic Use
- 10 Apr 2018 New trial record